Profile data is unavailable for this security.
About the company
Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
- Revenue in SEK (TTM)0.00
- Net income in SEK-54.94m
- Incorporated2017
- Employees4.00
- LocationScandion Oncology A/SFruebjergvej 3, Koebenhavn OeKOEBENHAVN 2100DenmarkDNK
- Websitehttps://scandiononcology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paion AG | -1.12tn | -1.12tn | 798.22k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| Scandion Oncology A/S | 0.00 | -54.94m | 1.06m | 4.00 | -- | 0.0857 | -- | -- | -0.2764 | -0.2764 | 0.00 | 0.0528 | 0.00 | -- | -- | 0.00 | -138.75 | -- | -186.13 | -- | -- | -- | -- | -- | -- | -- | 0.0079 | -- | -- | -- | 6.49 | -- | -- | -- |
| MagForce AG | 3.94m | -118.31m | 2.01m | 69.00 | -- | 0.0067 | -- | 0.5102 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
| Oxurion NV | 33.57k | 1.33m | 2.95m | 11.00 | -- | -- | 1.01 | 87.80 | -1.48 | -1.48 | 0.0014 | -3.46 | 0.0005 | -- | 0.0018 | 272.73 | 1.94 | -101.52 | -- | -249.96 | -1,333.33 | 53.85 | 3,966.67 | -2,672.68 | -- | 1.47 | 42.11 | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
Data as of Jul 02 2025. Currency figures normalised to Scandion Oncology A/S's reporting currency: Swedish Krona SEK
0.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 94.07k | 0.04% |
Data from 30 May 2025 - 30 May 2025Source: FactSet Research Systems Inc.
